SGLT2 inhibitor is a new type of hypoglycemic drug, the representative drugs are Dagliflozin and Englestrin, the main mechanism of action is to promote the excretion of excess sugar in the blood to the urine, and at the same time inhibit the reabsorption of sugar by the renal tubules, through increasing the urinary sugar to reduce the effect of blood sugar. For example, Dagliflozin excretes an average of 75g of sugar per day, and Englestrin excretes an average of 100g of sugar per day, which can have a weight loss effect for diabetic patients. It is important to note that these drugs should not be used if the patient has a previous urinary tract infection or reproductive system infection.